Botulinum toxin - A treatment for migraine? A systematic review

Pain Medicine

Volumn 7, Issue 5, 2006, Pages 386-394

  Gupta, Vinod Kumar ^a  

^a Dubai eGovernment Dubai Police   (United Arab Emirates)

Author keywords

Botulinum toxin; Evidence based medicine; Migraine; Placebo effect

Indexed keywords

AMITRIPTYLINE; AMYL NITRITE; BOTULINUM TOXIN A; DONEPEZIL; ISOPRENALINE; NEUROPEPTIDE; NIFEDIPINE; PLACEBO; PROPRANOLOL;

ANALGESIA; ANALGESIC ACTIVITY; ANTINOCICEPTION; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TRANSPORT; HUMAN; MIGRAINE; MUSCLE RELAXATION; MUSCLE SPASM; NONHUMAN; PAIN; PROPHYLAXIS; REVIEW; SCALP; SKELETAL MUSCLE; SYSTEMATIC REVIEW;

ANIMALS; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS, TYPE A; DISEASE MODELS, ANIMAL; EVIDENCE-BASED MEDICINE; HUMANS; MICE; MIGRAINE DISORDERS; NEUROPEPTIDES; NOCICEPTORS; PLACEBO EFFECT; RATS; RECEPTORS, SENSORY; SENSORY RECEPTOR CELLS; SPASM; TRIGEMINAL NERVE;

EID: 33749078243     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2006.00216.x     Document Type: Review

References (85)

1. Yokoyama T, Kumon H, Smith CP, Somogyi GT, Chancellor MB. Botulinum toxin treatment of urethral and bladder dysfunction. Acta Med Okayama 2002; 56: 271-7.
2. Schiavo G, Santucci A, Dasgupta BR, et al. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett 1993; 335: 99-103.
3. Dolly O. Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins. Headache 2003; 43 (suppl 1): 16-24.
4. Dolly JO, Black JD, Williams RS, Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature 1984; 307 (457): 460.
5. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981; 79: 734-70.
6. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990; 53: 633-9.
7. Grazko MA, Polo KB, Jabbari M. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995; 45: 712-7.
8. Schnider P, Binder M, Kittler H, et al. A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol 1999; 140: 677-80.
9. Kolbasnik J, Waterfall WE, Fachnie B, et al. Long-term efficacy of Botulinum toxin in classical achalasia: A prospective study. Am J Gastroent 1999; 94: 3434-9.
10. Smith CP, Somogyi GT, Chancellor MB. Botulinum toxin: Poisoning the spastic bladder and urethra. Rev Urol 2002; 4: 61-8.
11. Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain 2002; 18 (suppl 6): S142-6.
12. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43 (suppl 1): 9-15.
13. Silberstein SD, Aoki KR. Botulinum toxin type A: Myths, facts, and current research. Headache 2003; 43 (suppl 1): 1.
14. Evans RW, Blumenfeld A. Botulinum toxin injections for headache. Headache 2003; 43: 682-5.
15. Dodick DW. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: From bench to bedside. Headache 2003; 43 (suppl 1): 25-33.
16. Blumenfeld A. Botulinum toxin type A for the treatment of headache: Pro. Headache 2004; 44: 825-30.
17. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. 2nd edition. Cephalagia 2004; 24 (suppl 1): 9-160.
18. Perfetto EM, Morris LS. Agency for Health Care Policy and Research clinical practice guidelines. Ann Pharmacother 1996; 30: 1117-21.
19. Voller B, Sycha T, Gustorff B, et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 2003; 61: 940-4.
20. Kramer HH, Angerer C, Erbguth F, Schmelz M, Birklein F. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003; 250: 188-93.
21. Blersch W, Schulte-Mattler WJ, Przywara S, etal. Botulinum toxin A and the cutaneous nociception in humans: A prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 2002; 205: 59-63.
22. Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47: 614-24.
23. Cui M, Khanijou S, Rubino J, Kei Roger Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125-33.
24. Nixdorf DR, Heo G, Major PW. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain 2002; 99: 465-73.
25. Edvinsson L. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache. CNS Drugs 2001; 53: 167-78.
26. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache 2004; 44: 35-43.
27. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000; 38: 245-58.
28. Olesen J, Diener H-C, Husstedt IW, etal. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 1104-10.
29. Goadsby PJ, Hoskin KL, Knight YE. Substance P blockade with the potent and centrally acting antagonist GR205171 does not affect central trigeminal activity with superior sagittal sinus stimulation. Neuroscience 1998; 86: 337-43.
30. May A, Goadsby PJ. Pharmacological opportunities and pitfalls in the therapy of migraine. Curr Opin Neurol 2001; 14: 341-5.
31. Diener HC. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 2003; 23: 183-5.
32. Blau JN. Migraine: Theories of pathogenesis. Lancet 1992; 339: 1202-7.
33. Welch KMA. Botulinum toxin type A for the treatment of headache: Con. Headache 2004; 44: 831-3.
34. Binder WJ, Brin MF, Blitzer A, etal. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study. Otolaryngol Head Neck Surg 2000; 123: 669-76.
35. Mauskop A, Basdeo R. Botulinum toxin A is an effective prophylactic therapy for migraines [abstract]. Cephalalgia 2000; 20: 422.
36. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache 2000; 40: 445-50.
37. Brin MF, Swope DM, O'Brien C, Abbasi S, Pogoda JM. Botox® for migraine: Double-blind, placebo-controlled, region-specific evaluation. Cephalalgia 2000; 20: 421-2.
38. Barrientos N, Chana P. Efficacy and safety of botulinum toxin type A (BOTOX®) in the prophylactic treatment of migraine. Presented at: American Headache Society 44th Annual Scientific Meeting; June 21-23, 2002; Seattle, WA. Abstract S106.
39. Eross EG, Dodick DW. The effects of Botulinum toxin type A on disability in episodic and chronic migraine. Presented at: American Headache Society 44th Annual Scientific Meeting, June 21-23, 2002; Seattle, WA. Abstract S108.
40. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: A randomized, placebo-controlled, parallel-design study. Cephalalgia 2004; 24: 60-5.
41. Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine-A randomized, double-blind, placebo-controlled study. Cephalalgia 2004; 24: 838-43.
42. Evers S, Rahmann A, Vollmer-Haase J, Husstedt I-W. Treatment of headache with botulinum toxin A-A review according to evidence-based medicine criteria. Cephalalgia 2002; 22: 699-710.
43. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000; 43: 249-59.
44. Alam M, Arndt KA, Dover JS. Severe, intractable headache after injection with botulinum A exotoxin: Report of 5 cases. J Am Acad Dermatol 2002; 46: 62-5.
45. Mathew NT. Drug-induced headache. Neurol Clin 1990; 8: 903-12.
46. Sheean GL, Murray NM, Marsden CD. Pain and remote weakness in limbs injected with botulinum toxin A for writer's cramp. Lancet 1995; 346: 154-6.
47. Welch KMA. A 47 year old woman with tension-type headaches. JAMA 2001; 286: 960-6.
48. Schmitt WJ, Slowey E, Fravi N, Weber S, Burgunder JM. Effect of botulinum toxin A injections in the treatment of chronic tension type headache: A double blind, placebo-controlled trial. Headache 2001; 41: 658-44.
49. Burch CM, Kokoska MS, Glaser DA, Hollenbeak CS. Treatment of frontal tension headaches with botulinum toxin A. Cephalalgia 2001; 21: 486-91.
50. Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R. Treatment of tension-type headache with botulinum toxin A: A double-blind, placebo-controlled study. Headache 2000; 40: 300-5.
51. Silberstein SD. Neurotoxins in the neurobiology of pain. Headache 2003; 43 (suppl 1): 2-8.
52. Ranson R, Igarashi H, MacGregor EA, Wilkinson M. The similarities and differences of migraine with aura and migraine without aura: A preliminary study. Cephalalgia 1991; 11: 189-92.
53. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-Current understanding and treatment. N Engl J Med 2002; 346: 257-70.
54. Silberstein SD, Young WB. Migraine aura and prodrome. Semin Neurol 1995; 15: 175-82.
55. Hupp SL, Kline LB, Corbett JJ. Visual disturbances of migraine. Surv Ophthlamol 1989; 33: 221-36.
56. Nicolodi M, Galeotti N, Ghelardini C, Bartolini A, Sicuteri F. Central cholinergic challenging of migraine by testing second-generation anticholinesterase drugs. Headache 2002; 42: 596-602.
57. Pellandra CL. La geneserine-morphine adjuvant de l'anesthesia generale. Lyon Med 1933; 151: 653.
58. Yaksh TL, Dirksen R, Harty GJ. Antinociceptive effects of intrathecally injected cholinomimetic drugs in the rat and cat. Eur J Pharmacol 1985; 117: 81-8.
59. Smith MD, Yang X, Nha JY, Boccafusco JI. Antinociceptive effect of spinal cholinergic stimulation: Interaction with substance P. Life Sci 1989; 45: 1255-61.
60. 2 receptor systems. Anesthesiology 1994; 80: 1338-48.
61. 1 receptors. Br J Pharmacol 2000; 129: 1633-40.
62. Jankovic J, Schwartz K. Botulinum injections for cervical dystonia. Neurology 1990; 40: 277-80.
63. Gupta VK. Botulinum toxin for treatment of migraine: Randomized controlled trials versus basic sciences. J Neurol Neurosurg Psychiatry 2004. Published online July 12. Available at: http://jnnp.bmjjournals.com/cgi/eletters/75/7/951#212 (accessed August 6, 2006).
64. Poungvarin N. The first world report of botulinum A toxin injection for status migrainosus. J Med Assoc Thai 2001; 84: 1199-203.
65. Smuts JA, Barnard PW. Botulinum toxin type A in the treatment of headache syndromes: A clinical report on 79 patients [abstract]. Cephalalgia 2000; 20: 332.
66. Robbins L. Botulinum toxin A (Botox) for cluster headache: 6 cases. Cephalalgia 2000; 21: 499-500.
67. Freund BJ, Schwartz M. The use of botulinum toxin-A in the treatment of refractory cluster headache: Case reports. Cephalalgia 2000; 20: 329-30.
68. Brashear A, Lew MF, Dykstra DD, etal. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53: 1439-46.
69. Foster L, Clapp L, Erickson M, etal. Botulinum toxin A and chronic low back pain: A randomized, double-blind study. Neurology 2001; 56: 1290-3.
70. Difazio M, Jabbari B. A focused review of the use of botulinum toxins for low back pain. Clin J Pain 2002; 18 (suppl 6): S155-62.
71. de Paiva A, Meunier FA, Molgo J, etal. Functional repair of motor endplates after botulinum toxin-A poisoning: Bi-phasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci (USA) 1999; 96: 3200-5.
72. Carruthers A, Carruthers J. Update on the botulinum neurotoxins. Skin Ther Lett 2001; 6: 1-2.
73. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 2003; 250: 967-9.
74. Klein AW. Complications and adverse reactions with the use of botulinum toxin. Semin Cutan Med Surg 2001; 20: 109-20.
75. Bignall J. Science of placebos. Lancet 1994; 344: 904.
76. Johnson AG. Surgery as a placebo. Lancet 1994; 344: 1140-2.
77. Gupta VK. Is benign cough headache caused by intraocular haemodynamic aberration? Med Hypotheses 2004; 62: 45-8.
78. Herman J. Experiment and observation. Lancet 1994; 344: 1209-11.
79. Tfelt-Hansen P. Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on clinical trials in migraine. Cephalalgia 1991; 11: 1-12.
80. Karakurum B, Karaalin O, Coskun O, etal. The "dry-needle technique": Intramuscular stimulation in tension-type headache. Cephalalgia 2001; 21: 813-7.
81. Richardson P. Pain and the placebo effect. Acupunct Med 1992; 10: 9-11.
82. Guyuron B, Rose K, Kriegler JS, Tucker T. Hourglass deformity after botulinum toxin type A injection. Headache 2004; 44: 262-4.
83. Gupta VK. Bureaucratisation of migraine. Lancet Neurol 2004; 3: 396.
84. Gupta VK. Randomized controlled trials: The hijacking of basic sciences by mathematical logic. BMJ 2004. Published online July 6. Available at: http://bmj.bmjjournals.com/cgi/eletters/329/7456/2#65969 (accessed August 6, 2006).
85. Gupta VK. Magnesium therapy for migraine: Do we need more trials or more reflection? Headache 2004; 44: 445-6.